Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Batist

Showing results (41-50 of 165) with videos related to

Pageof 17
Sort By:
Bulletin Du Cancer|September 19, 2006
[The réseau de recherche sur le cancer: favoring a multi-disciplinary approach]Anne-Marie Mes-Masson, Louise Champoux, Josée Hébert, et al.
Clinical Breast Cancer|May 13, 2009
Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancerMaria Theodoulou, Gerald Batist, Susana Campos, et al.
Human Vaccines & Immunotherapeutics|May 2, 2015
Incidence of Epstein-Barr virus in Syrian women with breast cancer: A tissue microarray studyTahar Aboulkassim, Amber Yasmeen, Nizar Akil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapyVictor Cohen, Valerie Panet-Raymond, Nelly Sabbaghian, et al.
Frontiers in Pharmacology|March 14, 2013
Physician recruitment of patients to non-therapeutic oncology clinical trials: ethics revisitedLee Black, Gerald Batist, Denise Avard, et al.
Oncogene|May 4, 2004
Connexin43 pseudogene is expressed in tumor cells and inhibits growthMustapha Kandouz, Andrew Bier, George D Carystinos, et al.
Molecular Cancer Therapeutics|April 18, 2009
Connexin43 pseudogene in breast cancer cells offers a novel therapeutic targetAndrew Bier, Irene Oviedo-Landaverde, Jing Zhao, et al.
Current Oncology (Toronto, Ont.)|April 21, 2022
Access Denied? The Unintended Consequences of Pending Drug Pricing RulesAlan Kaplan, David J Stewart, Gerald Batist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2024
Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed TherapiesDavid J Stewart, Tim Ramsay, Vishal Navani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2013
Use of statins and the risk of death in patients with prostate cancerOriana Yu, Maria Eberg, Serge Benayoun, et al.
Pageof 17

Showing results (41-50 of 165) with videos related to

Sort By:
Pageof 17
Bulletin Du Cancer|September 19, 2006
[The réseau de recherche sur le cancer: favoring a multi-disciplinary approach]Anne-Marie Mes-Masson, Louise Champoux, Josée Hébert, et al.
Clinical Breast Cancer|May 13, 2009
Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancerMaria Theodoulou, Gerald Batist, Susana Campos, et al.
Human Vaccines & Immunotherapeutics|May 2, 2015
Incidence of Epstein-Barr virus in Syrian women with breast cancer: A tissue microarray studyTahar Aboulkassim, Amber Yasmeen, Nizar Akil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapyVictor Cohen, Valerie Panet-Raymond, Nelly Sabbaghian, et al.
Frontiers in Pharmacology|March 14, 2013
Physician recruitment of patients to non-therapeutic oncology clinical trials: ethics revisitedLee Black, Gerald Batist, Denise Avard, et al.
Oncogene|May 4, 2004
Connexin43 pseudogene is expressed in tumor cells and inhibits growthMustapha Kandouz, Andrew Bier, George D Carystinos, et al.
Molecular Cancer Therapeutics|April 18, 2009
Connexin43 pseudogene in breast cancer cells offers a novel therapeutic targetAndrew Bier, Irene Oviedo-Landaverde, Jing Zhao, et al.
Current Oncology (Toronto, Ont.)|April 21, 2022
Access Denied? The Unintended Consequences of Pending Drug Pricing RulesAlan Kaplan, David J Stewart, Gerald Batist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2024
Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed TherapiesDavid J Stewart, Tim Ramsay, Vishal Navani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2013
Use of statins and the risk of death in patients with prostate cancerOriana Yu, Maria Eberg, Serge Benayoun, et al.
Pageof 17